Asthma and COPD Management with Budecort and Foracort

Introduction to Medications

The American Thoracic Society recommends that Foracort (budesonide/formoterol combination) is superior to Budecort (budesonide alone) for patients with asthma or COPD requiring step-up therapy, as combination ICS/LABA therapy significantly reduces exacerbations, improves lung function, and enhances quality of life compared to inhaled corticosteroid monotherapy 1, 2
Budecort contains budesonide alone—an inhaled corticosteroid (ICS) that provides anti-inflammatory effects but no bronchodilation, according to the European Respiratory Society 3

The Global Initiative for Asthma recommends using Foracort when patients have persistent asthma symptoms despite ICS treatment alone, particularly in moderate-to-severe disease requiring step 3 care or higher 2
Foracort is indicated for COPD patients with FEV1 <60% predicted with respiratory symptoms and frequent exacerbations (≥2 moderate exacerbations or ≥1 severe exacerbation per year), as stated by the Global Initiative for Chronic Obstructive Lung Disease 4
Patients with blood eosinophil counts >300 cells/μL may derive additional benefit from the ICS component of Foracort, according to the American College of Chest Physicians 4

The European Respiratory Society warns that ICS-containing regimens (including Foracort) increase pneumonia risk by approximately 4%, with odds ratios of 1.38-1.48 for adverse events in COPD patients 1, 2
The American Thoracic Society notes that this risk is particularly elevated in older patients and those with lower BMI 4
Long-acting β2-agonists (like formoterol in Foracort) should never be used as monotherapy for asthma and must always be combined with inhaled corticosteroids, as recommended by the National Asthma Education and Prevention Program 2

The Global Initiative for Asthma and the Global Initiative for Chronic Obstructive Lung Disease recommend assessing disease control and evaluating exacerbation history to determine the need for combination therapy with Foracort 1, 2, 4
Eosinophil counts and pneumonia risk factors should be monitored to guide treatment decisions, according to the American College of Chest Physicians 4
The European Respiratory Society suggests considering triple therapy with a long-acting muscarinic antagonist (LAMA) if exacerbations continue on Foracort 4, 5